$2.500
-0.124 (-4.94%)Zum Schluss
LIMN im Vergleich zur Peergroup
In the context of the broader market, LIMN competes directly with industry leaders such as NRSN and ERNA. With a market capitalization of $3.35M, it holds a leading position in the sector. When comparing efficiency, LIMN's gross margin of N/A stands against NRSN's N/A and ERNA's N/A. Such benchmarking helps identify whether Liminatus Pharma Inc is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Liminatus Pharma Inc
Liminatus Pharma has shown a troubling financial performance with net income losses, including a staggering loss of -$8,168,927 in Q4 2025. The company has had a gross profit of $0 for multiple quarters, indicating severe operational challenges. The current ratio has improved to 1.12 in Q2 2026, suggesting some liquidity, but the overall financial outlook remains weak.
Financials
Ähnliche Artikel
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.